WAHO/WON 2020 Virtual Annual Conference  
Friday, August 21, 2020  
7:30 AM - 3:00 PM CDT  
Agenda

7:30 – 7:40 AM  Welcome & Introductions  
Ruth O’Regan, MD  
President, Wisconsin Association of Hematology and Oncology

7:40 – 8:35 AM  What’s New and What’s Next in Lung Cancer Immunotherapy  
Ticiana Leal, MD  
University of Wisconsin, Carbone Cancer Center

8:40 – 9:15 AM  Telehealth Beyond COVID-19  
Teri Bedard, RT(R)(T), CPC  
Revenue Cycle Coding Strategies, Inc.

9:15 – 10:00 AM  Networking Break/Virtual Resource Center

10:00 – 10:40 AM  Care in the Era of COVID-19 and NCCN Best Practices  
Daniel Mulkerin, MD  
University of Wisconsin, Carbone Cancer Center

10:45 – 11:15 AM  Fellows Research Presentation  
Marina N. Sharifi, MD, University of Wisconsin  
Ariel Kleman, MD, Medical College of Wisconsin

11:20 AM – 12:00 PM  Palliative Care During a Pandemic  
Toby Campbell, MD  
University of Wisconsin, Carbone Cancer Center

12:00 PM  Closing Remarks/Lunch/Resource Center  
Ruth O’Regan, MD  
President, Wisconsin Association of Hematology and Oncology

1:00 – 1:05 PM  Welcome & Introductions  
Ryan Mattison, MD  
Wisconsin Oncology Network (WON)
1:05 PM  WON/WAHO Grant Award
Ruth M. O'Regan, MD
President, Wisconsin Association of Hematology and Oncology

1:30 – 1:45 PM  UW15068: UWCCC Molecular Tumor Board Registry
Mark Burkard, MD, PhD
University of Wisconsin

1:45 – 2:00 PM  UW16112: Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel Followed by Dose Dense AC Regimen in Patients with Triple Negative Non-Metastatic Breast Cancer
Yee Chung Cheng, MD
Medical College of Wisconsin

2:00 – 2:15 PM  UW20037: Phase II Trial of Onapristone in Combination with Fulvestrant for Women with ER-positive, PR-Positive, and HER2-Negative Metastatic Breast Cancer after Progression on Aromatase and CDK4/6 Inhibitors
Sailaja Kamaraju, MD, MS
Medical College of Wisconsin

2:15 – 2:30 PM  UW16086: Bendamustine + Obinutuzumab Induction Chemoimmunotherapy with Risk-Adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma
Julie Chang, MD
University of Wisconsin

2:30 – 2:45 PM  UW19029: Phase 2 Trial of FOLFOX + Liposomal Irinotecan (+ Trastuzumab for Her2+) as a 1st Line Treatment of Metastatic Gastroesophageal Adenocarcinoma (GEA)
Nataliya Uboha, MD, PhD
Wisconsin Oncology Network

2:45 – 3:00 PM  Closing Remarks
Nataliya Uboha, MD, PhD
Wisconsin Oncology Network

Agenda as of 08.12.20 and subject to change.